Fewer monthly migraine days observed after 6 months of Vyepti vs. placebo

DENVER — Treatment with Vyepti was associated with a sustained reduction in the frequency of episodic and chronic migraines over 6 months, researchers reported at the American Headache Society annual scientific meeting.

Vyepti (eptinezumab-jjmr, Lundbeck) is a humanized monoclonal antibody that binds to calcitonin gene-related peptide ligand and blocks its binding to the receptor, the company stated in a press release. The preventive migraine treatment was developed for IV infusion administration over the course of 30 minutes.

In a post-hoc analysis of two phase 3 studies, treatment with eptinezumab resulted in a reduction of headache frequency across 6 months compared with placebo.

In the PROMISE-1 trial, 35.8% of participants receiving 100 mg eptinezumab and 37.4% receiving 300 mg experienced a reduction of at least one diagnostic category after 6 months, compared with 30.6% on placebo.

In the PROMISE-2 trial, 43% (100 mg) and 48.3% (300 mg) had a reduction of at least one diagnostic category, compared with 31.7% on placebo.

Results of both studies also showed that a second dose of eptinezumab may benefit patients who did not experience at least a 50% reduction in monthly migraine days after the first dose. The most common adverse reactions to eptinezumab were nasopharyngitis and hypersensitivity.

“These data continue to show the clinical benefit of Vyepti as a preventive treatment option for people with migraine,” Marija Geertsen, MD, vice president of U.S. medical affairs at Lundbeck, said in a released statement. “We remain committed to evolving and improving migraine care for those who are highly impacted by migraine and seeking different options to help break the vicious cycle of increasing migraine attacks and more acute treatment use.”